Company intelligence / Profile preview

mybacs

Zug, Zug, Switzerland

Ownership: Private
Development stage: Other

Overview

mybacs markets synbiotic nutritional supplements for gut health that contain selected bacterial cultures, prebiotic plant extracts, minerals, and vitamins, with their lead product "Dailybacs" available commercially. They have not published interventional clinical trial results, but their formulations are described as science-based and developed in collaboration with clinicians and microbiome specialists[1][4][5].

Therapeutic areas: ImmunologyMetabolic DisordersPsychiatryGastroenterologyDermatology
Modalities: Live biotherapeutic product therapyProbioticPrebioticPostbiotic
Industry: Food & Nutrition

Beyond the preview

Go deeper on mybacs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mybacs.

Explore the full profile